[Minutes, Advisory Committee to the Director GP-160 Meeting (1992: Bethesda, Maryland)]

97

1 to see it go.
2 Thank you.
3 CO-CHAIRMAN FAUCI: Sam, question?
4 DR. BRODER: I think what I'm going to say
5 is inherent in your presentation, but I would hope and
6 advocate for paying special attention to HLA in
7 various individuals and to recognize at least the
8 possibility based on the precedents in many settings
9 of the concept of immune response genes and the
10 special role that HLA-related immune response genes
11 may, in fact, play in murine models of retroviruses,
12 that we keep open the possibility that there may be
13 different vaccines that would work, depending on what
14 the HLA type or the immune response gene complement is
15 of a given individual and that among the things that
16 we think about is to at least try to have those data
17 available and to keep open the possibility that in
18 some future time, you would be able to fine-tune
19 vaccines, especially for retroviruses, not just in a
20 general sense, but to develop the HLA profile of an
21 individual and then say, "Well, Vaccine X would be
22 better for you" or "Vaccine Y would be better for
NEAL R. GROSS
COURT REPORTERS. AND TRANSCRISERS
1323 RHODE ISLAND AVENUE, N.W.
[phone] WASHINGTON, D.C. 20005 [phone]